Claims

1. The use of a dose of at least 10^8 $TCID_{50}$ (50% Tissue Culture Infective Dose) of an Modified Vaccinia virus Ankara (MVA) for the manufacture of a pharmaceutical composition for inducing a protective T- and B-cell immune response against an orthopoxvirus in a human neonate or infant of less than 6 months of age, wherein the MVA is MVA-BN deposited at ECACC under Accession No. V00083008 and is to be administered as a single dose.

2. The use of claim 1, wherein the human infant is less than 2 months of age.

3. The use of claim 1, wherein the pharmaceutical composition is for inducing a protective T- and B-cell immune response against a poxvirus in a human neonate.

4. The use of claim 1, wherein the pharmaceutical composition is to be administered to the human neonate within 72 hours after birth.

5. The use of claim 1, wherein the orthopoxvirus is a Vaccinia virus.

6. The use of claim 1, wherein the orthopoxvirus is smallpox.

7. The use of claim 1, wherein the MVA is a recombinant MVA.

8. The use of claim 7, wherein the T- and B-cell immune response is against a heterologous antigen encoded by the recombinant MVA.

9. The use of a dose of at least 10^8 $TCID_{50}$ (50% Tissue Culture Infective Dose) of an Modified Vaccinia virus Ankara (MVA) for the manufacture of a pharmaceutical composition for inducing a protective T- and B- cell immune response against an orthopoxvirus in a human neonate or infant of less than 6 months of age, wherein the pharmaceutical composition induces protective T- and B-cell responses against a poxvirus in the human neonate or infant within 2 weeks of the dose of the MVA, and wherein the MVA is MVA-BN deposited at ECACC under Accession No. V00083008 and is to be administered as a single dose.

10. The use of claim 9, wherein the human infant is less than 2 months of age.

11. The use of claim 10, wherein the pharmaceutical composition is for inducing a protective T- and B-cell response against a poxvirus in a human neonate.

12. The use of claim 10, wherein the pharmaceutical composition is to be administered to the human neonate within 72 hours after birth.

13. The use of claim 10, wherein the poxvirus is a Vaccinia virus.

14. The use of claim 10, wherein the poxvirus is smallpox.

15. The use of claim 10, wherein the MVA is a recombinant MVA.

16. The use of claim 15, wherein the T- and B-cell immune response is against a heterologous antigen encoded by the recombinant MVA.